CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015
Hosting May 21 Educational Investor Breakfast: Understanding QIDP and Other 21st Century Incentives for Developing and Marketing Anti-Infective Medicines
BRIDGEWATER, N.J., May 5, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases, announced that it will report first quarter 2015 financial results on May 7. Randy Milby, Chief Executive Officer of CorMedix, will host the investor conference call on Friday, May 8 at 9:00 a.m. EDT.
In order to participate in the conference call, please call 1-877-407-8031 (U.S.), 1-201-689-8031 (outside the U.S.). All participants who dial in will need to give the operator first and last name, company name and phone number. Reference: CorMedix. A replay of this call will be available at (U.S.):1-877-660-6853 (International): 1-201-612-7415 Conference ID #: 13609469.
Separately, CorMedix will participate in an educational investor breakfast in New York, "Understanding QIDP and Other 21st Century Incentives for Developing and Marketing Anti-Infective Medicines," on May 21, 2015 at the New York Palace Hotel. This investor event will be focused on the positive impact of the GAIN Act and the QIDP designation on investments in companies with anti-infective programs. The event is designed to help investors understand how leveraging various regulatory and commercial incentives translate to increased shareholder value. Speakers will include regulatory attorneys, legislators, industry executives and medical professionals. Investors interested in attending should contact Tirth Patel of Tiberend Strategic Advisors, Inc.: [email protected]. The event will also be webcast live and remain available following the live event. To access the webcast, please visit the Investor Relations section of the CorMedix website.
About CorMedix
CorMedix Inc. is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration and/or IV medications. Plans are in progress to expand commercial distribution into the United States, Asia, the Middle East, South America and Africa upon appropriate regulatory approval. For more information, visit www.cormedix.com.
Logo - http://photos.prnewswire.com/prnh/20141204/162388LOGO
SOURCE CorMedix Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article